Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before...

Full description

Bibliographic Details
Format:	Article
Language:	English
Published:	Elsevier BV 2021
Online Access:	https://hdl.handle.net/1721.1/136118

Similar Items

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
by: Regev, Aviv
Published: (2022)

Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy
by: Chauhan, Vikash P, et al.
Published: (2021)

Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy
by: Chauhan, Vikash P., et al.
Published: (2022)

Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy
by: Zhang, Chi, et al.
Published: (2022)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
by: Chan, H, et al.
Published: (2010)

Research advance of natural products in tumor immunotherapy
by: Huo, Jin-Ling, et al.
Published: (2023)

Reprogramming the immune system.
by: Waldmann, H
Published: (2008)

Reprogramming the immune system.
by: Waldmann, H
Published: (2002)

REPROGRAMMING THE IMMUNE-SYSTEM
by: Waldmann, H, et al.
Published: (1993)

Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy.
by: Browning, M, et al.
Published: (1993)

Activation of human dendritic cells for immunotherapy in ovarian carcinoma
by: Brencicova, E, et al.
Published: (2012)

Cell-specific metabolic reprogramming of tumors for bioactivatable ferroptosis therapy
by: Li, Yanan, et al.
Published: (2022)

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
by: Palmer, D, et al.
Published: (2009)

Antibody engineering for tumor immunotherapy
by: Graff, Christilyn Paula
Published: (2005)

Reprogramming the immune system using antibodies.
by: Graca, L, et al.
Published: (2006)

Reprogramming the immune system towards regulation
by: Waldmann, H, et al.
Published: (2010)

Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells
by: Suvà, Mario L., et al.
Published: (2017)

iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
by: Horton, C, et al.
Published: (2019)

Advancements in reprogramming strategies for the generation of induced pluripotent stem cells.
by: Lai, Mei I., et al.
Published: (2011)

Immune monitoring in cancer immunotherapy.
by: Romero, P, et al.
Published: (2000)

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
by: Chuah, Samuel, et al.
Published: (2022)

Solid tumor immunotherapy with T cell engager-armed oncolytic viruses
by: Scott, E, et al.
Published: (2017)

Reprogramming the immune system for tolerance with monoclonal antibodies.
by: Cobbold, S, et al.
Published: (1990)

Prospects for reprogramming the immune system in multiple sclerosis
by: Waldmann, H
Published: (2007)

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
by: Cochran, Jennifer R, et al.
Published: (2017)

Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis
by: Moreno-Cubero, E, et al.
Published: (2016)

A Phase II trial of dendritic cell (DC) immunotherapy for hepatocellular carcinoma
by: Midgley, R, et al.
Published: (2004)

Comprehensive molecular characterization of clear cell renal cell carcinoma
by: Getz, Gad Asher, et al.
Published: (2018)

Grading and prognostic factors of papillary renal cell carcinoma
by: Zhang, Stella Yun Ting
Published: (2010)

Partial nephrectomy for renal cell carcinoma in single kidneys
by: Henderson, A, et al.
Published: (2008)

Roles for Innate Immunity in Combination Immunotherapies
by: Moynihan, Kelly Dare, et al.
Published: (2018)

Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors
by: Xin, Gang, et al.
Published: (2017)

Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors
by: van de Beek, Irma, et al.
Published: (2023)

Renal cell carcinoma with retro-aortic renal vein thrombus: a case series.
by: Marsh, H, et al.
Published: (2010)

Local Targeting of NAD + Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma
by: Li, Ming, et al.
Published: (2022)

Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors
by: Tonegawa, Susumu
Published: (2020)

WHO/ISUP grading of clear cell renal cell carcinoma and papillary renal cell carcinoma; validation of grading on the digital pathology platform and perspectives on reproducibility of grade
by: Browning, L, et al.
Published: (2021)

Exploiting the use of induced pluripotent stem cell derived immune cells for immunotherapy
by: Sachamitr, S
Published: (2015)

Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer
by: Moynihan, Kelly D. (Kelly Dare)
Published: (2018)

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
by: Schmid, Daniela, et al.
Published: (2018)